Drugs / HF50
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06822998 | Jun 2025 → Mar 2026 overdue | cancer | HighField Biopharmaceuticals Corporation | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07601334 | Jun 2026 → Jun 2028 expected | cancer | HighField Biopharmaceuticals Corporation | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HF50 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06822998 ↗ |
| Known as | TRAFsome | “It was also named a T cell Redirecting Antibody Fragment-anchored Liposomes (TRAFsome).” NCT06822998 ↗ |
| Action | Activate | “TLR7/8 agonist to activate innate immunity” NCT07601334 ↗ |
| Modality | Other / unclassified | “HF50 is a liposomal T-cell engager with an unique design based on the lipid bilayer.” NCT06822998 ↗ |
| Route | Intravenous | “receive HF50 via intravenous infusion” NCT06822998 ↗ |